Last updated on November 2017

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced EjectionFraction (VICTORIA)


Brief description of study

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced EjectionFraction (VICTORIA)

Detailed Study Description

Male and female subjects aged 18 years or older, with chronic HF (NYHA class II-IV), reduced ejection fraction (< 45%), elevated natriuretic peptides, and previous HFdecompensation (defined as HF hospitalization or use of IV diuretics for HF [without hospitalization]) will be enrolled in this trial.

Clinical Study Identifier: TX82104

Contact Investigators or Research Sites near you

Start Over

Research Center

Columbus Regional Research Institute
Columbus, GA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.